» Articles » PMID: 11859199

Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: an Experience of 405 Cases

Overview
Date 2002 Feb 23
PMID 11859199
Citations 176
Authors
Affiliations
Soon will be listed here.
Abstract

Just two and a half decades ago adult renal cell neoplasms, i.e., those arising from the renal tubules or collecting duct epithelium, were subdivided into two major subtypes: "clear cell carcinoma" and "granular cell carcinoma." Subsequent detailed morphologic and/or cytogenetic studies have resulted in the recognition of several distinctive subtypes of adult renal epithelial neoplasms, which has led to the promulgation of a refined contemporary histologic classification of these tumors. This study examines the prognostic significance of histologic subtyping in accordance with the new classification in a consecutive series of 405 cases treated at a single institution. Cases were histologically classified into 28 (7%) benign tumors [27 (6.7%) renal oncocytomas, 1 (0.2%) metanephric adenoma] and 377 (93%) malignant tumors [255 (63%) conventional (clear cell) renal cell carcinoma, 75 (18.5%) papillary renal cell carcinoma, 24 (5.9%) chromophobe renal cell carcinoma, and 23 (5.7%) renal cell carcinoma, unclassified]. A total of 25 (6.6%) malignant tumors showed evidence of sarcomatoid change. Kaplan-Meier survival analysis with log-rank test showed histologic type (p = 0.002), Fuhrman's nuclear grade (p = 0.001), TNM stage (p = 0.001), vascular invasion (p = 0.001), and necrosis (p = 0.001) to be significantly associated with disease-specific survival and progression-free survival, based on follow-up of 368 patients (mean 64.5 months, median 56 months). The 5-year disease-specific survival for chromophobe renal cell carcinoma, papillary renal cell carcinoma, conventional (clear cell) renal cell carcinoma, and renal cell carcinoma, unclassified was 100%, 86%, 76%, and 24%, respectively; no patient with a benign tumor diagnosis progressed or died of disease. The 5-year progression-free survival for chromophobe renal cell carcinoma, papillary renal cell carcinoma, conventional (clear cell) renal cell carcinoma, and renal cell carcinoma, unclassified was 94%, 88%, 70%, and 18%, respectively. Malignant tumors with sarcomatoid change had a 35% and 27%, 5-year disease-specific and progression-free survival, respectively. Cox proportional hazards regression analysis showed TNM stage (p = 0.001), nuclear grade (p = 0.01), and necrosis (p = 0.05) to be significant predictors of disease-specific survival. In conclusion, our study shows that the histologic categorization of adult renal epithelial neoplasms performed by routine light microscopic hematoxylin and eosin-based examination in accordance with the contemporary classification scheme has prognostic utility.

Citing Articles

Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation.

Baytok A, Ecer G, Balasar M, Koplay M J Clin Imaging Sci. 2025; 15:10.

PMID: 40041438 PMC: 11878704. DOI: 10.25259/JCIS_160_2024.


Clinical, pathological, and oncological outcomes in unclassified renal cell carcinoma compared to clear cell renal cell carcinoma.

Sawczyn G, Brambilla C, Rodrigues G, Pereira M, Cardili L, de Carvalho P Indian J Urol. 2025; 41(1):51-58.

PMID: 39886631 PMC: 11778684. DOI: 10.4103/iju.iju_256_24.


Clinical and molecular prognostic nomograms for patients with papillary renal cell carcinoma.

Wang X Discov Oncol. 2024; 15(1):780.

PMID: 39692801 PMC: 11655765. DOI: 10.1007/s12672-024-01669-8.


CT imaging analysis differentiating papillary renal neoplasm with reverse polarity from papillary renal cell carcinoma: combined with a radiomics model.

Lee H, Kim T, Cho J, Moon M, Moon K, Kim S Jpn J Radiol. 2024; 42(12):1458-1468.

PMID: 39046645 PMC: 11588810. DOI: 10.1007/s11604-024-01631-2.


Comprehensive molecular analyses and experimental validation of CDCAs with potential implications in kidney renal papillary cell carcinoma prognosis.

Li F, Wu Z, Du Z, Ke Q, Fu Y, Zhan J Heliyon. 2024; 10(12):e33045.

PMID: 38988558 PMC: 11234104. DOI: 10.1016/j.heliyon.2024.e33045.